Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login
The Cancer Letter Inc.
P.O. Box 9905
Washington, D.C. 20016
Tel: 202-362-1809
Fax: 202-595-1310

Documents Cited in The Cancer Letter

2014 - Volume 40


2013 Volume 39


2012 Volume 38

  • William Gimson's resignation letter, from the Cancer Prevention & Research Institute of Texas (The Cancer Letter, Dec. 14, 2012).
  • Confirmation of an inquiry by the Texas Office of the Attorney General into CPRIT's funding of Peloton Therapeutics (The Cancer Letter, Dec. 14, 2012).
  • The letter from CPRIT's founding legislators expressing concern to CPRIT's investigators (The Cancer Letter, Dec. 14, 2012).
  • The letter from the Travis County District Attorney to Kristen Doyle, CPRIT's general counsel (The Cancer Letter, Dec. 14, 2012).
  • CPRIT's announcement of the appointment of Margaret Kripke as chief scientific officer (The Cancer Letter, Dec. 14, 2012).
  • An audio recording of Kripke's telephone conference with reporters (The Cancer Letter, Dec. 14, 2012).
  • A letter from Richard Schilsky to his colleagues at the University of Chicago.
  • The American Society of Clinical Oncology's press release announcing Richard Schilsky being named chief medical officer.
  • University of Chicago's notice to faculty announcing Richard Schilsky being named chief medical officer of the American Society for Clinical Oncology.
  • MD Anderson's August 2012 Financials (The Cancer Letter, Oct. 12, 2012). 
  • A recording of MD Anderson President Ronald DePinho's State of the Institution speech (The Cancer Letter, Oct. 12, 2012). 
  • The CPRIT Email Archive obtained by The Cancer Letter detailing the agency's reaction to MD Anderson's incubator proposal (The Cancer Letter, Sept. 28, 2012).
  • UT System documents pertaining to the hiring of DePinho and Chin (The Cancer Letter, Sept. 21, 2012).
  • MD Anderson Moon Shots Program Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Breast and Ovarian Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: CLL Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Melanoma Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: AML MDS Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Lung Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • Robert DePinho's letter to Rep. Fred Upton (The Cancer Letter, Sept. 14, 2012).
  • AAMC's letter to Sen. Sheldon Whitehouse  (The Cancer Letter, Sept. 14, 2012).
  • AACR's letter to Sen. Sheldon Whitehouse  (The Cancer Letter, Sept. 14, 2012).
  • PANCan's Letter to Reps. Anna Eshoo and Leonard Lance  (The Cancer Letter, Sept. 14, 2012).
  • CLS's letter to Rep. Fred Upton  (The Cancer Letter, Sept. 14, 2012).
  • Pancreatic Cancer Action Network's advocacy materials packet including fact sheets for policymakers (The Cancer Letter, Aug. 3, 2012).
  • A document describing how N-CORP will be divided into levels 1, 2 and 3 (The Cancer Letter, July 13, 2012).
  • The MD Anderson-CPRIT Compliance Review Report (The Cancer Letter, June 15, 2012).
  • A transcript of MD Anderson President Ronald DePinho's appearance on CNBC (The Cancer Letter, June 1, 2012).
  • The MD Anderson IACS six-and-a-half-page-long grant application (The Cancer Letter, May 25, 2012).
  • The appendix to the IACS grant application, including budgets (The Cancer Letter, May 25, 2012).
  • Ronald DePinho's remarks to the Board of Visitors in October 2011 (The Cancer Letter, May 25, 2012).
  • The NCI Memo circulated before the cancer center directors' April 19 retreat (The Cancer Letter, May 11, 2012).
  • An outline of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • A draft of the 2013 CCSG Guidelines (The Cancer Letter, May 11, 2012).
  • A summary of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • Director Cullen's letter to NCI's Weiss (The Cancer Letter, May 11, 2012).
  • The letter sent by 11 cancer center directors to Weiss (The Cancer Letter, May 11, 2012).
  • The complaint filed by attorneys representing Timothy Kinsella against Amelia Weber (The Cancer Letter, April 20, 2012).
  • The Opposition to Seal, sent by attorneys representing Amelia Weber (The Cancer Letter, April 20, 2012).
  • Urorad Healthcare's FAQ sheet regarding developing IMRT centers (The Cancer Letter, April 13, 2012).
  • TwinCrest Group's flyer to urology practices offering in-office pathology (The Cancer Letter, April 13, 2012).
  • Part one of a collection of files containing Craig Thompson's Motion to Dismiss, filed as part of the Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • Part two of a collection of files containing Thompson's Motion to Dismiss (The Cancer Letter, March 23, 2012).
  • Agios Pharmaceuticals' Motion to Dismiss, filed against Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • UPenn's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • Attachments to UPenn's complaint (The Cancer Letter, March 9, 2012).
  • The Abramson Institute's complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Policies document (The Cancer Letter, Feb. 3, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Agreement document (The Cancer Letter, Feb. 3, 2012).
  • FDA's letter to the Division of Medical Oncology, Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • Letter to CDER from the Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • FDA Establishment Inspection Report, January 2011 (The Cancer Letter, Jan. 27, 2012).
  • NVCI co-founder Heather Murren's declaration in bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • Restructuring consultant George Pillari's declaration in NVCI's bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • The Cancer Letter's interview with Robert Young, former NCCN chairman: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
  • The Cancer Letter's interview with Catherine Harvey, NCCN's first executive director: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
  • The March 15, 1996, and Jan. 24, 1997, issues of The Cancer Letter (The Cancer Letter, Jan. 13, 2012).

2011 Volume 37

  • Anil Potti's application and letters of recommendation to the South Carolina licensure board (The Cancer Letter, Dec. 9, 2011).
  • Duke University's letter to the president of the North Carolina Medical Board (The Cancer Letter, Dec. 9, 2011).
  • NC Medical Board Reprimands Former Duke Doctor Anil Potti. The text of the consent decree.  
  • The email sent by Jerome Yates, former American Cancer Society VP for research, regarding the society's restructuring (The Cancer Letter, Nov. 18, 2011).
  • The TREAT Act, a model bill proposing two new options for FDA approval (The Cancer Letter, Nov. 18, 2011).
  • NCI CTEP's RFA Presentation to the Board of Scientific Advisors (The Cancer Letter, Nov. 11, 2011).
  • Exhibit E: Spreadsheets showing the overfill of Aranesp compared to Procrit, in US & Westmoreland vs. Amgen (The Cancer Letter, Oct. 28, 2011).
  • The whistle-blower lawsuit of US & Westmoreland vs. Amgen Inc. (The Cancer Letter, Oct. 28, 2011).
  • The US Preventive Services Task Force Systematic Review Of Evidence Draft Paper, via Annals of Internal Medicine (The Cancer Letter, Oct. 7, 2011).
  • The jointly filed lawsuit against Duke University, Duke University Health System, Potti, Nevins, et al. (The Cancer Letter, Sept. 9, 2011).
  • The filed lawsuit of Joyce Shoffner vs. Duke University, et al. (The Cancer Letter, Sept. 9, 2011).
  • Citizen Oncology Foundation's analysis of the drug shortage (The Cancer Letter, Sept. 9, 2011).
  • FDA CDER's Post-Hearing Submission against Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
  • Genentech's Post-Hearing Submission in favor of Avastin's MBC Indication (The Cancer Letter, Aug. 12, 2011).
  • The letter to Varmus and Doroshow from advocates for the Children's Oncology Group (The Cancer Letter, July 8, 2011).
  • The letter to Varmus and Doroshow from patients involved in the adult cancer cooperative groups (The Cancer Letter, July 8, 2011).
  • Aug. 5, 2005 issue of The Cancer Letter (The Cancer Letter, July 1, 2011).
  • Claudia Henschke's affadavit used in class action suits against Philip Morris USA (The Cancer Letter, June 24, 2011).
  • The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, June 24, 2011).
  • The caBIG Program Update presented to the Board of Scientific Advisors (The Cancer Letter, June 24, 2011).
  • The First CALGB Protocol (The Cancer Letter, June 17, 2011).
  • The GAO's Decision to deny Velos' request for reconsideration (The Cancer Letter, June 17, 2011).
  • FDA CDER's Summary of Arguments supporting withdrawal of Avastin's breast cancer indication (The Cancer Letter Special Issue, May 27, 2011).
  • Genentech's Pre-Hearing Summary of Evidence in support of maintaining Avastin's accelerated approval (The Cancer Letter Special Issue, May 27, 2011).
  • The 2009 tax filing by Henschke's Early Diagnosis and Treatment Research Foundation, Inc (The Cancer Letter, April 29, 2011). 
  • The 2009 tax filing by Henschke's Foundation for Lung Cancer: Early Detection, Prevention & Treatment (The Cancer Letter, April 29, 2011). 
  • Velos protests NCI's decision to award a contract related to caBIG to Medidata (The Cancer Letter, April 22, 2011).
  • The FDA's Avastin Decision Memorandum (The Cancer Letter, April 15, 2011).
  • The CMS Provenge Decision Memo (The Cancer Letter, April 1, 2011).
  • The Duke University official account of the history of the scandal (The Cancer Letter, April 1, 2011).
  • The press release announcing the merger of ACOSOG, CALGB and NCCTG.
  • BSA caBIG Assessment (The Cancer Letter, March 4, 2011).
  • Response to CL Questions (The Cancer Letter, March 4, 2011).
  • UPDATED Response to CL Questions (The Cancer Letter, March 4, 2011).
  • Jeremy Berg - SMRB Comments (The Cancer Letter, Feb. 25, 2011).
  • Velos GAO Decision 11-28-2008 (The Cancer Letter, Feb. 25, 2011).
  • Velos GAO Decision 12-14-2009 (The Cancer Letter, Feb. 25, 2011).
  • Velos Letter to Varmus (The Cancer Letter, Feb. 25, 2011).
  • Original Award Doc to Velos from DOI (The Cancer Letter, Feb. 25, 2011).
  • NCI Medidata Award Notification (The Cancer Letter, Feb. 25, 2011).
  • Notice of Cancellation 12-15-10 (The Cancer Letter, Feb. 25, 2011).
  • NCI - Velos Selected for Award Powerpoint (The Cancer Letter, Feb. 25, 2011).
  • The letters from HHS to Congress regarding NCATS and NCRR (The Cancer Letter, Feb. 11, 2011).
  • A transcript of the NIH town hall conference call with NCRR stakeholders (The Cancer Letter, Feb. 11, 2011).
  • A transcript of the NIH town hall conference call with CTSA principal investigators (The Cancer Letter, Feb. 11, 2011).
  • The SMRB final report of their Dec. 7 meeting, voting to approve the plan for NCATS (The Cancer Letter, Feb. 11, 2011).
  • GOG White Paper argues for keeping the group separate (The Cancer Letter, Feb. 4, 2011). 
  • Duke pre-IDE filing on Lung Metagene Score (The Cancer Letter, Jan. 28, 2011).
  • FDA response to Duke pre-IDE filing (The Cancer Letter, Jan. 28, 2011).
  • Internal Duke document listing trials and their regulatory status (The Cancer Letter, Jan. 28, 2011).
  • Lisa McShane Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
  • Robert Becker Testimony before IOM (The Cancer Letter, Jan. 28, 2011).
  • New Timeline of the Duke Scandal; Lung Metagene Score data (The Cancer Letter, Jan. 14, 2011).
  • Internal NCI documents (zip files 1, 2 and 3) related to the Duke genomics controversy (The Cancer Letter, Jan. 7, 2011).

2010 Volume 36

  • NIH response to Sen. Charles Grassley on sponsored travel by NCI scientists (The Cancer Letter, Dec. 3, 2010).
  • NCI-funded CISNET model presented by Harvard researchers predicting outcome of National Lung Screening Trial (The Cancer Letter, Nov. 26, 2010).
  • Sen. Charles Grassley letter to NIH Director Francis Collins and NCI Director Harold Varmus on "sponsored travel" by NCI scientists (The Cancer Letter, Oct. 29, 2010.)
  • NCI letter of Oct. 15, 2010 on carboplatin dosing, referenced in The Cancer Letter, Oct. 22, 2010.
  • NCI Letter of Oct. 1, 2010, "Action Letter for Protocols Sponsored by the National Cancer Institute That Use Carboplatin." Referenced in The Cancer Letter, Oct. 8, 2010.
  • Documents on Avastin referenced in Sept. 3, 2010, issue of The Cancer Letter: Howard Burris letter; AdvancedBC.org letter; advocacy groups' letter to FDA; Kathy Miller letter to ES103 investigators; Gabriel Hortobagyi email; National Breast Cancer Coalition letter to FDA.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 30, 2010: Potti's bio submitted to Department of Defense.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 23, 2010: Letter by 33 biostatisticians to NCI Director Harold Varmus. Letter by American Cancer Society Chief Medical Officer Otis Brawley to Duke University. A list of Potti's technologies available for licensing from Duke. More detailed description of one of these technologies.
  • Duke scientist Anil Potti's different CVs: version 1version 2, and version 3. His University of North Dakota Residency application, and a page from a Duke brochure listing his claimed Rhodes scholarship. The Cancer Letter, July 16, 2010.
  • City of Hope dispute with for-profit physician group reading materials (.zip file), referenced in The Cancer Letter, May 28, 2010.
  • Entertainment Industry Foundation's 2008 IRS Form 900, referenced in The Cancer Letter, May 21, 2010.
  • Documents on Duke University genomics research: Duke report and email obtained by The Cancer Letter; comments by biostatisticians on the report (The Cancer Letter, May 14, 2010).
  • Letters by American Society of Clinical Oncology and the Massachusetts Hospital Association protesting Mass. Blues restrictions on ESAs (The Cancer Letter, April 9. 2010).
  • Analysis of industry-sponsored phase I studies prepared by The Cancer Letter for article in March 26, 2010, issue.
  • NCI concept statements: Barrett's Esophagus Translational Research Network and Commercial Application and Use of Emerging Molecular Analysis Technologies (SBIR) (The Cancer Letter, March 19, 2010).
  • NCI concept statement: Clinical Proteomic Technologies for Cancer (The Cancer Letter, March 12, 2010).
  • Documents (zip file) in Allergan lawsuit against FDA over off-label use promotion (The Cancer Letter, Jan. 15, 2010).
Letter